E-LIB Suche - Ergebnisse für: Atkins, Michael B.

1

Clinical Outcomes of Immune Checkpoint Inhibitors in Unique..:

Shah, Neil J. ; Della Pia, Alexandra ; Wu, Tianmin...
Cancers. 16 (2024) 12 - p. 2223 , 2024

Link: https://doi.org/10.3390/..

2

Long-Term Survival in Patients With Relapsed/Refractory Adv..:

Beckermann, Kathryn E ; Asnis-Alibozek, Aviva G ; Atkins, Michael B...
The Oncologist. 29 (2024) 3 - p. 254-262 , 2024

Link: https://doi.org/10.1093/..

3

Treatment-free survival outcomes from the phase II study of..:

Atkins, Michael B ; Jegede, Opeyemi A ; Haas, Naomi B...
Journal for ImmunoTherapy of Cancer. 12 (2024) 4 - p. e008293 , 2024

Link: https://doi.org/10.1136/..

4

Durability of Response with First-Line Combined Immune Chec..:

Zaemes, Jacob ; McDermott, David F. ; Regan, Meredith M..
Kidney Cancer. 8 (2024) 1 - p. 93-97 , 2024

Link: https://doi.org/10.3233/..

5

Plain Language Summary Looking at How Long Side Effects Las..:

Rini, Brian I ; Atkins, Michael B ; Choueiri, Toni K...
Future Oncology. 19 (2023) 40 - p. 2623-2629 , 2023

Link: https://doi.org/10.2217/..

6

Impact of COVID-19 in patients on active melanoma therapy a..:

Johnson, Douglas B. ; Atkins, Michael B. ; Hennessy, Cassandra...
BMC Cancer. 23 (2023) 1 - p. , 2023

Link: https://doi.org/10.1186/..

7

A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab..:

McKay, Rana R ; Leucht, Katharina ; Xie, Wanling...
The Oncologist. 29 (2023) 4 - p. 324-331 , 2023

Link: https://doi.org/10.1093/..

8

Multi-omic profiling reveals discrepant immunogenic propert..:

In, Gino K. ; Ribeiro, Jennifer R. ; Yin, Jun...
npj Precision Oncology. 7 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..

9

Re: Matthew S. Ernst, Vishal Navani, J. Connor Wells, et al..:

Regan, Meredith M. ; Atkins, Michael B. ; McDermott, David F.
European Urology. 84 (2023) 4 - p. e96-e97 , 2023

Link: https://doi.org/10.1016/..

10

Phase II study of nivolumab and salvage nivolumab/ipilimuma..:

Atkins, Michael B ; Jegede, Opeyemi A ; Haas, Naomi B...
Journal for ImmunoTherapy of Cancer. 11 (2023) 3 - p. e004780 , 2023

Link: https://doi.org/10.1136/..

11

LITESPARK-024: A randomized phase 1/2 study of belzutifan w..:

McDermott, David F ; Peer, Avivit ; Agarwal, Neeraj...
The Oncologist. 28 (2023) Supplement_1 - p. S11-S11 , 2023

Link: https://doi.org/10.1093/..

12

Addressing resistance to PD-1/PD-(L)1 pathway inhibition: c..:

Zhang, Tian ; Forde, Patrick M ; Sullivan, Ryan J...
Journal for ImmunoTherapy of Cancer. 11 (2023) 5 - p. e006555 , 2023

Link: https://doi.org/10.1136/..

13

Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitini..:

Plimack, Elizabeth R. ; Powles, Thomas ; Stus, Viktor...
European Urology. 84 (2023) 5 - p. e123-e124 , 2023

Link: https://doi.org/10.1016/..

14

The effect of neighborhood socioeconomic disadvantage on sm..:

Walter, Angela Wangari ; Lee, Ju‐Whei ; Streck, Joanna M....
Cancer. 130 (2023) 3 - p. 439-452 , 2023

Link: https://doi.org/10.1002/..

15

Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitini..:

Plimack, Elizabeth R. ; Powles, Thomas ; Stus, Viktor...
European Urology. , 2023

Link: https://doi.org/10.1016/..